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Abstract 
The biodistribution of liposomal antigens either encapsulated in or surface-linked to liposomes of similar composition was studied 
over time following intravenous injection and the results analyzed in relation to adjuvanticity. The two formulations were shown to 
behave very differently in vivo. While encapsulated antigen was rapidly focused to liver and spleen as expected, surface-linked antigen 
exhibited a more disseminated distribution which parallels that of the free protein. In dual-labelling experiments, it was also shown that 
encapsulated antigen remains associated with its liposomal vehicle in contrast to surface-linked antigen which is rapidly dissociated. This 
dissociation was apparently neither due to an exchange with plasma lipoproteins nor to a direct action of blood constituents. Besides, it 
was found that surface-linked antigen was rapidly accumulated in the carcass. We propose that the retention of the surface-linked antigen 
in the carcass results from a pre-processing of the protein involving more probably mononuclear phagocytes. This pre-processing might in 
turn favor the dissociation of the protein from the liposomes in a form that allows its dissemination in the whole organism and its 
interaction with more efficient antigen presenting cells such as for example Langerhans or dendritic cells. 
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1. Introduction 
Liposomes are artificial membranous vesicles mainly 
composed of synthetic or naturally occurring phospho- 
lipids, which may be associated with other hydrophilic or 
hydrophobic substances. Their intrinsic properties such as 
biodegradability, low toxicity or poor immunogenicity have 
raised hopes of their eventual use as drug carrier systems 
in body fluids [I]. However, their rapid removal from 
circulation by mononuclear phagocytes of the reticulo-en- 
dothelial system (RES) and their inability to cross the 
endothelial barrier [2-41 have largely discredited their 
therapeutic usefulness until the recently described strate- 
gies to prolong their survival time in vivo [S]. Although the 
Abbreviations: RES, reticuloendothelial system; DMPC, dimyristoyl- 
phosphatidylcholine; DPPE, dipalmitoylphosphatidylethanolamine; SPDP, 
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privileged interactions of standard liposomes with the RES 
have hampered most of their hypothesized applications, 
this specific property is nevertheless considered as a poten- 
tial advantage in immunomodulation studies since RES 
tissues are the physiological sites in which immune cells 
are mainly located and in which immune responses are 
elaborated. Liposomes were, in fact, soon recognized as 
potent stimulators of the immune response provided they 
are physically associated with an antigen whether by en- 
capsulation in the aqueous phase or exposition at the 
liposomal surface [6-81. 
The immunoadjuvant character of liposomes first re- 
ported by Allison and Gregoriadis in 1974 [9] is generally 
attributed to the rapid and efficient targeting of antigen to 
macrophages of the RES capable of initiating the immune 
response by presenting processed antigen to helper T cells 
[lo- 121. However, the investigations which have at- 
tempted to demonstrate the details of this postulated mech- 
anism are somewhat fragmentary and have yielded con- 
flicting results [ 13-161. The question is particularly puz- 
zling since macrophages are apparently not the best induc- 
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tive antigen presenting cells for virgin T cells 117,181. 
Other mechanisms to adjuvanticity that have been pro- 
posed for alun or Freund’s adjuvant such as depot forma- 
tion at the site of injection or activation of co-stimulatory 
signals have also been hypothesized for liposomal antigens 
but have never been systematically tested [19,20]. 
While a physical linkage of the antigen to the liposome 
appears to be the exclusive condition for immunopotentia- 
tion, important differences between encapsulated and sur- 
face-linked liposomal antigens were reported for all as- 
pects of the immune response analyzed namely kinetics, 
intensity and quality of the humoral response, in vitro 
proliferation of presensitized cells or cytokine production 
[21-241. These observations suggest that both Iiposomal 
formulations are differently handled by the immune system 
leading consequently to the activation of distinct immune 
pathways and to the induction of specific effector func- 
tions. This behavioral difference could in turn be used to 
advantage in the design of vaccines capable of stimulating 
the type of protection relevant to the cure of specific 
pathogenic diseases. The source of these differences re- 
mains to be identified but it might be speculated to reside 
in the steps that follow the introduction of an antigen in 
the organism. 
Numerous biodistribution and pharmacokinetics studies 
have analyzed the in vivo destiny of injected liposomes as 
a function of dose, charge, fluidity, size, surface hydro- 
philicity or route of injection in order to identify the 
liposomal formulations capable of avoiding the RES and 
hence survive for longer periods in body fluids, with a 
view for their exploitation for drug transport. Large doses, 
neutral charges or shielded negative charges, small size, 
bilayer rigidity, surface hydrophilicity and subcutaneous or 
intramuscular route of penetration were all shown to corre- 
late with prolonged survival in body fluids through de- 
creased uptake by the RES [2,20,25-271. The relationship 
between RES avoidance and adjuvanticity has however 
been less frequently investigated [20,28] in spite of the 
numerous studies of those liposomal properties necessary 
for adjuvanticity [ 11,29].Since surface-linked antigens in- 
duce a more potent stimulation of immune responses than 
their encapsulated counterparts, both in intensity and dura- 
tion, and since the immunopotency of liposomal formula- 
tions is generally associated with their uptake by the RES, 
it seems reasonable to suppose that surface-linked antigens 
are focused and retained more efficiently by the RES than 
encapsulated antigens. We approached this question by 
comparing the biodistribution of both liposomal antigenic 
formulations following intravenous injection. This route of 
penetration was chosen since it was previously shown to 
induce the strongest response [24,30]. The results we ob- 
tained invalidate our initial hypothesis since surface-linked 
antigen was neither focused to nor retained more effi- 
ciently by RES tissues. However, they also suggest some 
alternative explanation to the increased adjuvanticity of 
surface-linked antigen. 
2. Materials and methods 
2.1. Materials 
Conalbumin, dimyristoylphosphatidylcholine (DMPC), 
dipalmitoylphosphatidylethanolamine (DPPE), cholesterol, 
3-(2-pyridyldithio)propionic acid N-hydroxysuccinimide 
ester (SPDP), 1,3,4,6-tetrachloro-3a,6a-diphenylglycouril 
(IODOGEN) were purchased from Sigma (St. Louis, MO). 
lz51, protein iodination grade was obtained from New 
England Nuclear Canada (Lachine, Quebec) and 
[ “HIcholesterol (46 Ci/mmoI) from Amersham Canada 
(Oakville, Ontario). ScintiVerse II, a micro-emulsified 
scintillation cocktail was obtained from Fisher Scientific. 
2.2. Animals 
Male and female BALB/c mice, the offsprings of 
breeding pairs obtained from Charles River Canada (St. 
Constant, Quebec), were used between 8 and 12 weeks of 
age. 
2.3. Liposomes 
Liposomes made of DMPC, cholesterol and DPPE in a 
molar ratio 63:31:6 were prepared by an extrusion tech- 
nique (Lipex Biomembranes Inc., Vancouver, BC) using 
polycarbonate filters with a pore size of 0.2 pm as previ- 
ously described 1311. Conalbumin, our model antigen, was 
either encapsulated in the course of liposome formation or 
surface-linked to preformed liposomes containing DPPE 
modified with the heterobifunctional reagent SPDP by the 
method of Leserman, Machy and Barbet 1321. 
2.4. Biodistribution studies 
Liposomes labelled with either [ 3H]cholesterol (I 
&i/pm00 or 1251-conaIbumin (1100 cpm/,ug) prepared 
by the IODOGEN method of Salacinski et al. [33] were 
injected into mice via the tail vein. Each animal received a 
total of 30 pug conalbumin either free or associated to 
liposomes at a mean protein/lipid ratio of 20 pg/hmoI 
phospholipid. 
At varying times after injection, mice were bled by 
cardiac puncture under ether anaesthesia, killed by cervical 
dislocation and dissected. All tissue samples were weighed 
and the level of radioactivity determined either by gamma- 
or scintillation counting depending on the isotope ana- 
lyzed. 
For tritiated cholesterol measurements, tissues were first 
extracted with isopropanol/heptane/ 1 N H, SO, (40: 10: 1, 
v/v> according to the method of Kedar et al. 1341. 
Tissue samples were obtained from liver, spleen, lung, 
heart, kidney, brain, inguinal lymph nodes and blood. In 
some cases, the remaining carcass was also considered. 
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Fig. I. Three to five mice were injected intravenously with either free (stippled bars), encapsulated (hatched bars) or surface-linked (black bars) iodinated 
conalbumin as described in Section 2. Radioactivity was measured in blood, liver, spleen, kidneys, brain, heart, lungs and inguinal lymph nodes. The 
percentage of recovered radioactivity was calculated for each tissue. The results obtained for blood, liver and spleen are expressed as mean f S.E. 
The radioactivity of each sample was corrected for blood 
content according to Allen [35]. 
The effect of blood on the antigen association to lipo- 
somes was analyzed using heparinized whole blood. 
Briefly, 1 ml of freshly drawn blood was incubated at 37°C 
for various time periods in the presence of identical 
amounts of either free, encapsulated or surface-linked anti- 
gen (0.15 ml). At the end of incubation, samples were 
centrifuged at 4°C for 30 min at 145 000 X g, after which 
the radioactivity of the pellet and supematant was mea- 
sured. 
3. Results 
The distribution in blood, liver and spleen of iodinated 
conalbumin, in the free state, surface-linked to, or encapsu- 
lated within liposomes is shown in Fig. 1. As can be seen, 
the antigen, when encapsulated, leaves the circulation 
rapidly and is concentrated mainly in liver and spleen, in 
agreement with its expected behavior. Surprisingly how- 
ever, surface-linked antigen which our previous work has 
shown to be the most immunopotent formulation, behaves 
as the free protein, remaining predominantly in the circula- 
tion and being cleared at a comparable rate. 
The specific radioactivity of different tissue samples, an 
index of the accumulation of antigen that should be tightly 
related to the biological activity of the formulation, is 
presented in Table 1. From these data, it can be seen that 
encapsulated antigen is not only focused rapidly and equally 
to liver and spleen but also retained more efficiently in 
these organs; whereas the specific activity of most tissues 
decreases roughly by an order of magnitude during a 24 h 
period, that of spleen and liver only decreases by a factor 
of 2. The surface-linked antigen, on the other hand, like 
the free protein, is more widely disseminated throughout 
the organism and does not exhibit any specific tissue 
accumulation. Although 1 h following injection the protein 
Table 1 
Specific radioactivity (cpm/g tissue) of various organs of mice injected with iodinated conalbumin, free, encapsulated or surface-linked to liposomes 
Organ Radioactivity recovered (cpm per g tissue) 
after 1 h after 5 h after 24 h 
free ag encaps. linked free ag encaps. linked free ag encaps. linked 
Blood 13028 2088 10399 5445 1326 4538 292 120 658 
Brain 229 27 165 83 30 58 9 36 50 
Heart 5633 1156 5533 2193 1255 1119 152 173 311 
Lung 3246 2239 4339 1453 2121 1062 183 559 323 
Spleen 383 13081 1337 229 14853 368 21 5817 66 
Liver 3018 11196 1718 196 8935 485 121 6129 134 
Kidney 3861 1534 3042 1491 3173 912 250 255 196 
L.N. a 1996 1647 1697 1262 162 529 364 0 160 
RE/blood 0.26 12 0.29 0.19 
Liver/spleen 7.9 0.86 1.29 3.47 
All tissue counts were normalized to 63 000 cpm injected per animal. 
a L.N. = inguinal lymph nodes. 
18 0.19 0.5 1 104 0.30 
0.6 1.32 4.42 1.16 2.03 
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is detected in the circulation as well as in heart, lungs, 
kidney or inguinal lymph nodes, the specific activity of 
these tissues rapidly declines with time without showing 
any significant tissular preference. The only difference that 
can be demonstrated between surface-linked and free anti- 
gen is a slight bias of the latter in favor of the liver over 
the spleen. The biodistribution was followed over 21 days 
but neither free, encapsulated nor surface-linked antigen 
could be recovered in significant amount even 5 days after 
injection. 
The possibility that the unexpected behavior of surface- 
linked antigen could be related to a massive dissociation of 
the protein from its liposomal vehicle was analyzed by 
examining the biodistribution of liposomal cholesterol, one 
of the major constituent of the liposomal membrane. Fig. 2 
compares the percentage of labelled cholesterol and la- 
belled conalbumin recoveries in the three major tissues 
(blood, liver and spleen) and for both liposomal formula- 
tions. The results confirm that liposomes with encapsulated 
conalbumin are mainly focused to liver and that the protein 
remains essentially associated with the liposomal vehicle 
over the period examined (A). However, in the case of 
surface-linked antigen, a large discrepancy appears be- 
tween the distributions of labelled conalbumin and labelled 
cholesterol (B); the liposomes exit from the circulation to 
gain access to liver and spleen whereas the protein remains 
in the circulation suggesting thereby that it is dissociated 
from the liposomes. The difference observed between both 
distributions is already highly significant 1 h post-injection 
with a P value < 0.005. It is also observed that the 
disappearance of liposomes from the circulation occurs at 
a slower rate than that of encapsulated homologues sug- 
gesting that the surface association of the protein prolongs 
the half-life of liposomes within the circulation (P < 0.005 
1 h post-injection). 
We also investigated the possibility that surface-linked 
antigen is either detached from the liposomal vehicle by 
hydrolysis of the disulfide linkage or degraded to some 
extent by plasma proteinases. The results (Table 2) indi- 
cate that after 1 h, neither encapsulated nor surface-linked 
antigen appears to be significantly dissociated from lipo- 
somes in the presence of blood since only about 15% of 
Cholesterol Conalbumin 
1 
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Time (fi; 
23 
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Fig. 2. Encapsulated (A) and surface-linked (B) antigens were made with either tritiated cholesterol or iodinated conalbumin. At different t imes following 
injection, the radioactivity was measured in liver, blood and spleen. The results represent the mean of 3-5 mice + S.E. Error bars were omitted for 
S.E. < 2%. 0: liver. W: blood. 0: spleen. 
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Fig. 3. Iodinated covalently-linked~&thtigens were injected intra- 
venously and all animal tissues were analyzed for their radioactivity 
content at various times post-injection. The total radioactivity recovered 
is compared to that recovered in blood. The results are expressed as the 
mean percentage + S.E. of the recovered radioactivity relative to injected 
dose. S.E. values inferior to 2% are not indicated. 0: surface-linked 
antigen, total recovery. n : surface-linked-antigen, blood recovery. 0: 
free antigen, total recovery. 0 : free antigen, blood recovery. 
the protein can be recovered in the supematant after a 30 
min ultracentrifugation at 145 000 X g, conditions used to 
separate excess free antigen from liposomes during their 
preparation. The amount of protein recovered in the super- 
natant increases slightly over time, indicating that the 
exposed antigen is accessible to dissociation processes in 
the circulation. The possibility that this dissociation in- 
volves the transfer of conalbumin to plasma lipoproteins 
was also considered, but under our experimental conditions 
spectrophotometric analysis shows that the lipoproteins 
remain primarily in the supematant. 
Our results thus raise the question of the immunopo- 
tency of surface-linked antigen in a situation where no 
accumulation can be demonstrated in liver or spleen and 
where its behavior is apparently undistinguishable from 
that of the free protein. Part of the answer to this question 
is provided by our investigations of the distribution of 
blood liver carcass 
Table 2 
Percentage of iodinated conalbumin recovered in a 145000X g super- 
natant following incubation in presence of blood 
Exp. 1 
Conalbumin recovered in supematant (%) 
lh 
Free 
Encapsulated 
Surface-linked 
Exp. 2 
f37*3.0 
13t 1.7 
9kO.4 
lh 5h 24 h 
Surface-linked 17t5.3 24k5.1 32+2.3 
Free or liposomal antigenic formulations were incubated in the presence 
of heparinized murine blood for the time periods indicated as described in 
Section 2. Each result represents the meankS.E. of three independent 
determinations. 
antigen in the whole animal. Although surface-linked anti- 
gen disappears from the circulation at the same rate as free 
conalbumin and is not preferentially localized in any major 
organ, the recovery of linked antigen is more important 
(Fig. 3). As shown in Fig. 4, this difference can be 
essentially attributed to a significantly increased accumula- 
tion of the antigen in the carcass and more specifically in 
skin and muscles of the limbs. 
4. Discussion 
This study is the first to compare the biodistribution of 
two liposomal antigenic formulations of similar lipid com- 
position but differing by their type of physical association 
with a protein antigen. Our results clearly show that the 
covalent linkage of a protein to the surface of liposomes 
differently influences the tissue distribution of the protein 
when compared to encapsulation. 
Most studies of the immunopotentiating properties of 
liposomes have been carried out with encapsulated antigen 
I 24h 
-7 
blood liver carcass 
TISSUE 
blood liver ~areas~ 
Fig. 4. Iodinated surface-linked (Ml or free (0) antigens were injected intravenously and the percentage of injected dose recovered in blood, liver and 
carcass was calculated. The results are expressed as mean percentage + S.E. 
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while biodistribution studies have been carried out with 
empty liposomes of various composition or with drug- 
loaded liposomes in the context of drug-targeting strate- 
gies. The biodistribution studies have concluded unani- 
mously that liposomes administered parenterally are rapidly 
focused to macrophages of the major organs of the RES, 
the liver and spleen, a major disadvantage for most of their 
eventual pharmacological uses [36]. These studies have 
also largely contributed to set the dogma that macrophage 
targeting constitutes the main justification to liposomal 
adjuvanticity by facilitating the rapid processing and effi- 
cient presentation of antigen [20,21,37]. The dogma was 
comforted by several evidences showing that macrophage 
depletion strongly suppresses the immune response to lipo- 
somal antigens [38,39]. 
Our own findings with encapsulated antigen are in 
agreement with this established dogma: the antigen and its 
vehicle are rapidly cleared from the circulation and are 
both accumulated predominantly by the liver and spleen. 
The antigen remains in these organs at a significant level 
for the first 24 h and then subsequently disappears so that 
after 5 days, the antigen is no longer detectable within the 
limits of sensitivity of our assay techniques. 
The behavior of surface-linked antigen, on the other 
hand, is in flagrant disagreement with the established 
dogma. Our initial finding was that the antigen remains 
mainly in the circulation, being somewhat disseminated in 
other tissues but apparently avoiding the spleen and liver. 
Moreover, after 24 h, the recovery of surface-linked anti- 
gen was significantly less (2.6%) than that of encapsulated 
antigen (15.4 f 2%) but comparable to the 1.4% observed 
for the free antigen. We were thus forced to conclude that 
surface-linked antigen was neither rapidly focused to, nor 
efficiently retained by RES tissues in spite of the pro- 
nounced adjuvant properties of this liposomal formulation. 
By following the fate of the lipid component of lipo- 
somes carrying surface-linked antigen, we also observed 
that these liposomes have a longer half-life (by a factor of 
3-4) in comparison to liposomes carrying encapsulated 
antigen. This may be the result of the shielding of the lipid 
membrane by the surface-exposed protein, thereby increas- 
ing surface hydrophilicity, a mechanism which has been 
invoked as an explanation to the prolonged circulation of 
stealth liposomes [40]. On the other hand, the absence of 
colocalization of the antigen and its carrier suggests that 
the protein is rapidly dissociated and circulates in blood 
mainly in a non-liposomal form that apparently behaves 
like free antigen. 
The question was particularly puzzling since we and 
others have previously demonstrated that liposomes do not 
potentiate the specific humoral response to a protein anti- 
gen unless the two are physically associated [6-S]. If the 
protein was indeed dissociated from its carrier in the 
circulation, not only would we have expected it to behave 
similarly to free protein but also to have similar adjuvant 
properties. Since this was not the case, we were forced to 
question more deeply the fate of the surface-linked anti- 
gen. 
Using heparinized blood, we found no evidence of 
significant proteolytic degradation of the exposed antigen. 
This result suggests that blood constituents only play a 
minor role, if any, in the observed distribution of surface- 
linked antigen. Since our experimental conditions did not 
however reproduce the exact conditions prevailing in vivo, 
a role for blood constituents cannot be totally excluded. 
More importantly, we found that the surface-linked antigen 
escapes from the circulation and reaches peripheral tissues 
such as the skin and the limbs in significant amount. 
Although the free antigen was also recovered in the same 
areas, only 5% of the injected dose was recovered in these 
sites 24 h following injection as opposed to the 20% 
recovered with surface-linked antigen. The results taken 
together indicate that the surface-linked antigen recovered 
in tissues, while dissociated from liposomes, nevertheless 
differs from free antigen since the two behave differently. 
The possibility that the protein-DPPE complex has been 
exchanged between liposomes and plasma lipoproteins may 
be ruled out since under the centrifugation conditions used 
to analyze the role of blood in the dissociation process, 
lipoproteins are only pelleted to a limited extent. 
The nature of the difference between free and surface- 
linked antigen remains to be established. While we are not 
able at this time to totally exclude a role for blood 
components, the difference in adjuvanticity reported for 
free and surface-linked antigen together with the reported 
importance of macrophages in adjuvanticity calls for some 
alternative explanations. It may be speculated that some 
transformations occur outside the circulation in areas where 
liposomes initially accumulate, such as for example the 
liver or spleen. The linked antigen that gains access to 
these major lymphoid tissues may be sufficient for the 
observed adjuvanticity of this type of liposomal formula- 
tion. On the other hand, we may also imagine that 
surface-linked antigen is partially degraded in endocytic 
compartments of phagocytic cells and regurgitated in the 
circulation under a modified, possibly lipopeptidic form, 
that can easily cross the endothelial barrier. The modified 
peptide may in turn be more readily accessible to special- 
ized antigen-presenting cells of the skin or diffuse lym- 
phoid tissues, and more efficiently presented. This latter 
conjecture is consistent with the observation that 
macrophages are not very good activators of virgin T cells 
[17,18] and that other cells may have to be more directly 
involved in the initiation of the immune response to liposo- 
ma1 antigens. Dendritic cells could be potential candidates 
for this process since they have been shown to take up 
peptides generated by extracellular proteolysis or regurgi- 
tated by other cells, since they can retain antigen more 
efficiently than other types of antigen presenting cells and 
since their uptake function, unlike that of macrophages, 
does not appear to be related to antigen clearance or 
destruction [18]. This hypothesis may also explain the 
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results of Su and Van Rooijen [39] showing that 
macrophage depletion is more detrimental to the adjuvant 
properties of surface-linked antigen than to that of the 
encapsulated form. If encapsulated antigen can be released 
in a free form accessible to non-phagocytic antigen-pre- 
senting cells even in the absence of macrophages, phago- 
cytosis may be an obligate prerequisite to the processing or 
pre-processing of surface-linked protein. Our supposition 
that lipopeptides are involved is based on the finding that 
lipopeptides enhance both major histocompatibility com- 
plex class II-restricted presentation to T cells [41] and 
cell-mediated immunity [42]. Surface-linked antigen has 
also been shown to stimulate the production of interferon-y, 
the characteristic cytokine of this type of immunity [24]. 
In conclusion, this comparative biodistribution study of 
two liposomal antigenic formulations reveals a clear differ- 
ence in the circulation of antigen depending on its mode of 
association with the liposomal vehicle that have to be 
considered in the understanding of their adjuvant potential. 
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